These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8004415)

  • 1. Approaches to reducing subvisible particle counts in lyophilized parenteral formulations.
    Gupta PK; Porembski E; Williams NA
    J Pharm Sci Technol; 1994; 48(1):30-7. PubMed ID: 8004415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes.
    Kasper JC; Troiber C; Küchler S; Wagner E; Friess W
    Eur J Pharm Biopharm; 2013 Oct; 85(2):294-305. PubMed ID: 23747745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
    Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
    Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subvisible Particulate Contamination in Cell Therapy Products-Can We Distinguish?
    Vollrath I; Mathaes R; Sediq AS; Jere D; Jörg S; Huwyler J; Mahler HC
    J Pharm Sci; 2020 Jan; 109(1):216-219. PubMed ID: 31521641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation.
    Davis JM; Zhang N; Payne RW; Murphy BM; Abdul-Fattah AM; Matsuura JE; Herman AC; Manning MC
    Pharm Dev Technol; 2013; 18(4):883-96. PubMed ID: 22813478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Particulate contamination in parenterals: current issues.
    Groves MJ
    Boll Chim Farm; 1991 Oct; 130(9):347-54. PubMed ID: 1799429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of primary packaging on the quality of parenteral products.
    Solomun L; Ibric S; Boltic Z; Djuric Z; Stupar B
    J Pharm Biomed Anal; 2008 Nov; 48(3):744-8. PubMed ID: 18786797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent.
    Gibson M; Denham AJ; Taylor PM; Payne NI
    J Parenter Sci Technol; 1990; 44(6):306-13. PubMed ID: 2277318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particulate evaluation of parenteral nutrition solutions by electronic particle counting and scanning electron microscopy.
    Akers MJ; Schrank GD; Russell S
    Am J Hosp Pharm; 1981 Sep; 38(9):1304-7. PubMed ID: 6792911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In line final filters for removing particles from amphotericin B infusions.
    Huber RC; Riffkin C
    Am J Hosp Pharm; 1975 Feb; 32(2):173-6. PubMed ID: 237416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lyophilization on parenteral emulsions.
    Krishna G; Sheth BB
    PDA J Pharm Sci Technol; 1999; 53(6):318-23. PubMed ID: 10754731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new coincidence model for single particle counters, Part I: Theory and experimental verification.
    Knapp JZ; Abramson LR
    J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP perspectives on particle contamination of injectable products.
    Gallelli JF; Groves MJ
    J Parenter Sci Technol; 1993; 47(6):289-92. PubMed ID: 8120733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new coincidence model for single particle counters, Part II: Advances and applications.
    Knapp JZ; Lieberman A; Abramson LR
    PDA J Pharm Sci Technol; 1994; 48(5):255-92. PubMed ID: 8000900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upflow anaerobic sludge blanket reactor--a review.
    Bal AS; Dhagat NN
    Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
    Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.